Burhan Ferhanoğlu

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · The Lancet Oncology · 2014 · 388 citations

Medicine, Oncology, Pharmacotherapy +8

Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study

Anas Younes, Joshua Brody, Cecilia Carpio et al. · The Lancet Haematology · 2019 · 195 citations · Full text

Life Sciences, Immunology, Oncology +15

Aspirin inhibits interleukin 1-induced prostaglandin H synthase expression in cultured endothelial cells.

Kenneth K. Wu, Radhika Sanduja, Alissa Tsai et al. · Proceedings of the National Academy of Sciences · 1991 · 139 citations

Life Sciences, Biochemistry, Pharmacology +11

Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL

Fritz Offner, Olga Samoilova, Evgenii A. Osmanov et al. · Blood · 2015 · 135 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +7

Overview of 321 patients with idiopathic thrombocytopenic purpura

G.E. Pamuk, Ömer Nuri̇ Pamuk, Zafer Başlar et al. · Annals of Hematology · 2002 · 93 citations

Medicine, Hematology, Pathology +8